SEARCH

SEARCH BY CITATION

References

  • Ahluwalia, N. (1997) Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure. American Journal of Kidney Diseases, 30, 532541.
  • Auerbach, M., Ballard, H., Trout, R., Mellwain, M., Ackerman, A., Balirain, H., Balan, S., Barker, L. & Rana, J. (2004) Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. Journal of Clinical Oncology, 22, 13011307.
  • Auerbach, M., Ballard, H. & Glaspy, J. (2007) Clinical update: intravenous iron for anaemia. The Lancet, 369, 15021504.
  • Bailie, G.R. (2005) Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrology, Dialysis, Transplantation, 20, 14431449.
  • Bastit, L., Vanderbroek, A., Altintas, S., Gaede, B., Pinter, T., Suto, T.S., Mossman, T.W., Smith, K.E. & Vasteenkiste, J.F. (2008) Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Journal of Clinical Oncology, 26, 16111618.
  • Beamish, M.R., Davies, A.G., Eakins, J.D., Jacobs, A. & Trevett, D. (1971) The measurement of reticuloendothelial iron release using iron-dextran. British Journal of Haematology, 21, 617622.
  • Beguin, Y. (1995) Quantitative assessment of erythropoiesis in haemodialysis patients demonstrates gradual expansion of erythroblasts during constant treatment with recombinant human erythropoietin. British Journal of Haematoogy, 89, 1723.
  • Beguin, Y. (2005) Intravenous iron and recombinant human erythropoietin in cancer patients. Journal of Clinical Oncology, 23, 651652.
  • Bennett, C.L., Silver, S.M., Djulbegovic, B., Samaras, A.T., Blau, C.A., Gleason, K.J., Barnato, S.E., Elverman, K.M., Courtney, D.M., McKoy, J.M., Edwards, B.J., Tigue, C.C., Raisch, D.W., Yarnold, P.R., Dorr, D.A., Kuzel, T.M., Tallman, M.S., Trifilio, S.M., West, D.P., Lai, S.Y. & Henke, M. (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA: the journal of the American Medical Association, 27, 914924.
  • Bohlius, J., Wilson, J., Seidelfeld, J., Piper, M., Schwarzer, G., Sandercock, J., Trelle, S., Weingart, O., Bayliss, S., Djulbegovic, B., Bennett, C.L., Langensiepen, S., Hyde, C. & Engert, A. (2006) Recombinant human erythropoietin in cancer patients: updated meta-analysis of 57 studies including 9353 patients. Journal of the National Cancer Institute, 98, 708714.
  • Bokemeyer, C., Aapro, M.S., Courdi, A., Foubertd, J., Linke, H., Osterborg, A., Repetto, L. & Soubeyran, B. (2007) EORTC guidelines for the use of erythropoietic proteins in anemic patients with cancer: 2006 update. European Journal of Cancer, 43, 258270.
  • Bovy, C., Gothot, A., Delanaye, P., Warling, X., Krzesinski, J.M. & Beguin, Y. (2007) Mature erythrocyte parameters as new markers of functional iron deficiency in hemodialysis: sensitivity and specificity. Nephrology, Dialysis, Transplantation, 22, 11561162.
  • Brugnara, C. (2000) Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function. Critical Reviews in Clinical Laboratory Sciences, 37, 93130.
  • Brugnara, C. (2003) Iron deficiency and erythropoiesis: new diagnostic approaches. Clinical Chemistry, 49, 15731578.
  • Brugnara, C., Schiller, B. & Moran, J. (2006) Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states. Clinical and Laboratory Haematology, 28, 303308.
  • Cavill, I. (2002) Erythropoiesis and iron. Best Practice & Research. Clinical Hematology, 15, 399409.
  • Cavill, I., Auerbach, M., Bailie, G., Barrett-Lee, P., Kaltwasser, P., Littlewood, T., Macdougal, I.C. & Wilson, K. (2006) Iron and the anaemia of chronic disease: a review and strategic recommendations. Current Medical Research and Opinion, 22, 731737.
  • Cazzola, M., Messinger, D., Battistel, V., Bron, D., Cimoni, R., Enller-Ziegler, L., Essers, U., Greil, R., Grossi, A., Jager, G., LeMevel, A., Najman, A., Silingardi, V., Spriano, M., Van Hoof, A. & Ehmer, B. (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response. Blood, 86, 44464453.
  • Cazzola, M., Ponchio, L., Pedrotti, C., Farina, G., Cerani, P., Lucotti, C., Novella, A., Rovati, A., Bergamaschi, G. & Beguin, Y. (1996) Prediction of response to recombinant human erythropoietin in anemia of malignancy. Haematologica, 81, 434441.
  • Cazzola, M., Beguin, Y., Kloczko, J., Spicka, I. & Coiffier, B. (2003) Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. British Journal of Haematology, 122, 386393.
  • Chang, J., Bird, R., Clague, A. & Carter, A. (2007) Clinical utility of serum soluble transferrin receptor levels and comparison with bone marrow iron stores as an index for iron-deficient erythropoiesis in a heterogeneous group of patients. Pathology, 39, 349353.
  • Charytan, C., Qunibi, W. & Bailie, G.R. (2005) Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron. Clinical Practice, 100, 5562.
  • Chertow, G.M., Mason, P.D., Vaage-Nielsen, O. & Ahlmen, J. (2006) Update on adverse drug events associated with parenteral iron. Nephrology, Dialysis, Transplantation, 21, 378382.
  • Collins, H.L. (2003) The role of iron in infections with intracellular bacteria. Immunology Letters, 85, 193195.
  • Coyne, D. (2006) Iron indices: what do they really mean? Kidney International, 69, 48.
  • Eschbach, J.W., Egrie, J.C., Downing, M.R., Browne, J.K. & Adamson, J.W. (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. New England Journal of Medicine, 316, 7378.
  • Fishbane, S., Frei, G.L. & Maesaka, J. (1995) Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. American Journal of Kidney Diseases, 26, 4146.
  • Fishbane, S., Ungureanu, V.D., Maesaka, J.K., Kaupke, C.J., Lim, V. & Wish, J. (1996) The safety of intravenous iron dextran in hemodialysis patients. American Journal of Kidney Diseases, 28, 529534.
  • Fishbane, S., Galgano, S., Langley, R., Canfield, W. & Maesaka, J.K. (1997) Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney International, 52, 217222.
  • Glaspy, J.A. (2002) The potential for anemia treatment to improve survival in cancer patients. Oncology (Williston Park), 16, 3540.
  • Glaspy, J., Bukowski, R., Steinberg, D., Taylo, C., Tchekmedyian, S. & Vadhan-Raj, D. (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. Journal of Clinical Oncology, 15, 12181234.
  • Goldberg, P. (2007) Danish researchers post long-awaited Aranesp results — ever so discreetly. Cancer Letters, 33, 16.
  • Goodnough, L.T. (2007) Erythropoietin and iron-restricted erythropoiesis. Experimental Hematology, 35, 167172.
  • Hedenus, M., Adriansson, M., San Miguel, J., Kramer, M.H., Schiperus, M.R., Juvonen, E., Taylor, K., Belch, A., Altes, A., Martinelli, G., Watson, D., Matcaham, J., Rossi, G. & Littlewood, T.J. (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. British Journal of Haematology, 122, 394403.
  • Hedenus, M., Birgegard, G., Nasman, P., Ahlberg, L., Karlsson, T., Lauri, B., Lundin, J., Larfars, G. & Osterborg, A. (2007) Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia, 21, 627632.
  • Hellstrom-Lindberg, E. (1995) Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. British Journal of Haematology, 89, 6771.
  • Hellstrom-Lindberg, E., Negrin, R., Stein, R., Krantz, S., Lindberg, G., Vardiman, J., Ost, A. & Greenberg, P. (1997) Erythroid response to treatment with G-CSF plus erythropoietin for anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. British Journal of Haematology, 99, 344351.
  • Henke, M., Laszig, R., Rube, C., Schafer, U., Haase, K.D., Schilcher, B., Mose, S., Beer, K.T., Burger, U., Dougherty, C. & Frommhold, H. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. The Lancet, 362, 12551260.
  • Henke, M., Mattern, D., Pepe, M., Bezay, C., Weissenberger, C., Werner, M. & Pajonk, F. (2006) Do erythropoietin receptors on cancer cells explain unexpected clinical findings? Journal of Clinical Oncology, 24, 47084713.
  • Henry, D., Abels, R. & Larholt, K. (1995) Prediction of response to recombinant human erythropoietin (r-huEPO/Epoietin a) in cancer patients. Blood, 85, 16761678.
  • Henry, D.H., Dahl, N.V., Auerbach, M., Tchekmedyian, S. & Laufman, L.R. (2007) Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. The Oncologist, 12, 231242.
  • Huang, X. (2003) Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutation Research, 533, 153171.
  • Hudson, J.Q. & Comstock, T.J. (2001) Considerations for optimal iron use for anemia due to chronic kidney disease. Clinical Therapy, 23, 16371671.
  • Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes (1998) A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. British Journal of Haematology, 103, 10701074.
  • Johnson, D.W., Herzig, K.A., Gissane, R., Campbell, S.B., Hawley, C.M. & Isbel, N.M. (2001) Oral versus intravenous iron supplementation in peritoneal dialysis patients. Peritoneal Dialysis International, 21, 231235.
  • Katodritou, E., Speletas, M., Zervas, K., Kapetanos, D., Georgiou, E., Christoforidou, A., Pavlitou, A., Sion, M. & Christakis, J. (2006) Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma. Laboratory Hematology, 12, 4754.
  • Katodritou, E., Zervas, K., Speletas, M., Kapetanos, D., Kartsios, C., Verrou, E., Banti, A., Effraimidou, S. & Christakis, J. (2007a) Hypochromic erythrocytes (%): a reliable marker of recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with multiple myeloma and lymphoma. Annals of Hematology, 86, 369376.
  • Katodritou, E., Verrou, E., Kapetanos, D., Bant, A., Kartsios, C., Mihou, D., Gastari, V., Markala, D., Effraimidou, S., Lazaridou, A., Terpos, E. & Zervas, K. (2007b) Sequential monitoring of erythrocyte hemoglobinization and iron markers during RHu-EPO therapy in anemic patients with multiple myeloma and lymphoma. Haematologica, 92(Suppl. 1), 28.
  • Laugsch, M., Metzen, E., Svensson, T., Depping, R. & Jelkmann, W. (2007) Lack of functional erythropoietin receptors of cancer cell lines. International Journal of Cancer, 22, 10051011.
  • Leyland-Jones, B., Semiglazov, V., Pawlicki, M., Pienkowski, T., Tjulandin, S., Manikhas, G., Makhson, A., Roth, A., Dodwell, D., Baselga, J., Biakhov, M., Valuckas, K., Voznyi, E., Liu, X. & Vercammen, E. (2005) Maintaining normal hemoglobin levels with epoetin alfa in mainly non-anemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. Journal of Clinical Oncology, 23, 59605972.
  • Littlewood, T. (2003) Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. The Oncologist, 8, 99107.
  • Littlewood, T.J., Bajetta, E., Nortier, J.W., Vercammen, E. & Rapoport, B. (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy. Results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 19, 28652874.
  • Ludwig, H. (1990) Erythropoietin treatment of anemia associated with multiple myeloma. New England Journal of Medicine, 322, 16931699.
  • Ludwig, H., Fritz, E., Leitgeb, C., Pecherstorfer, M., Samonigg, H. & Schuster, J. (1994) Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood, 84, 10561063.
  • Macdougall, I.C., Cavill, I., Hulme, B., Bain, B., McGregor, B., MacKay, P., Sanders, E., Coles, G.A. & Williams, J.D. (1992) Detection of functional iron deficiency during erythropoietin treatment: a new approach. British Medical Journal, 304, 2526.
  • Oncologic Drugs Advisory Committee (2007) Continuing Reassessment of the Risks of Erythropoiesis-stimulating Agents (ESAs) Administered for the Treatment of Anemia Associated with Cancer Chemotherapy. Food and Drug Administration, Rockville, MD, 10 May 2007 (Accessed 25 May, 2007, at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4301b2-00-index.htm).
  • Osterborg, A., Boogaerts, M.A., Cimino, R., Essers, U., Holowiecki, J., Juliusson, G., Jager, G., Najman, A. & Peest, D. (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma—a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin’s Lymphoma. Blood, 87, 26752682.
  • Osterborg, A., Brandberg, Y. & Hedenus., M. (2005) Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. British Journal of Haematology, 129, 206209.
  • Park, S., Grabar, S., Kelaidi, C., Beyne-Rauzy, O., Picard, F., Bardet, V., Coiteux, V., Leroux, G., Lepelley, P., Daniel, M.T., Cheze, S., Mahe, B., Ferrant, A., Ravoet, C., Escoffre-Barbe, M., Ades, L., Vey, N., Aljassem, L., Stamatoullas, A., Mannone, L., Dombret, H., Bourgeois, K., Greenberg, P., Fenaux, P., Dreyfus, F., for the GFM group. (2008) Predictive factors for response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood, 111, 574582.
  • Pedrazzoli, P., Farris, A., Del Prete, S., Del Gaizo, F., Ferrari, D., Blanchessi, C., Colucci, G., Desogus, A., Gamucci, T., Pappalardo, A., Fornarini, G., Pozzi, P., Fabi, A., Labianca, R., Di Costanzo, F., Secondino, S., Crucitta, E., Apolloni, F., Del Santo, A. & Siena, S. (2008) Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. Journal of Clinical Oncology, 26, 16191625.
  • Pettersson, T., Teppo, A.M. & Silmes, M.A. (1996) Circulating transferrin receptor during erythropoietin medication of anemic patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 25, 321324.
  • Rizzo, J.D., Somerfield, M.R., Hagerty, K.L., Seidenfeld, J., Bohlius, J., Bennett, C.L., Cella, D.F., Djulbegovic, B., Goode, M.J., Jakubowski, A.A., Rarick, M.U., Regan, D.H. & Lichtin, A.E. (2008) American Society of Clinical Oncology/American Society of Hematology 2007. Clinical practice guideline update on the use of epoetin and darbepoetin. Journal of Clinical Oncology, 26, 132149.
  • Sengölge, G., Horl, W.H. & Sunder-Plassmann, G. (2005) Intravenous iron therapy: well-tolerated, yet not harmless. European Journal of Clinical Investigation, 35(Suppl. 3), 4651.
  • Siedenfeld, J., Piper, M., Flamm, C., Hasselblad, V., Armitage, J.O., Bennett, C.L., Gordon, M.S., Lictin, A.E., Wade, III, J.L., Woolf, S. & Aronson, N. (2001) Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. Journal of the National Cancer Institute, 93, 12041214.
  • Sinclair, A.M., Todd, M.D., Forsythe, K., Knox, S.J., Elliot, S. & Begley, C.G. (2007) Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer, 110, 477488.
  • Steinmetz, T., Hellmoch, M., Neise, M., Aldaud, A., Lerchenmuller, C., Tsamaloukas, A., Fandel, F., Weiligmann, C., Totzke, U. & Schmitz, S. (2007) Prediction of the responsiveness to treatment with erythropoiesis-stimulating factors: a prospective clinical study in patients with solid tumors. Oncologist, 12, 748755.
  • Sullivan, J.L. (2004) Is stored iron safe? The Journal of Laboratory and Clinical Medicine, 144, 280284.
  • Sullivan, J. (2007) Long-term risks of increased use of intravenous iron. The Lancet, 370, 481482.
  • Terpos, E., Mougiou, A., Kouraklis, A., Chatzivassili, A., Michalis, E., Giannakoulas, N., Manioudaki, E., Lazaridou, A., Bakaloudi, V., Protopappa, M., Liapi, D., Grouzi, E., Parharidou, A., Symeonidis, A., Kokkini, G., Laoutaris, N.P., Vaipoulos, G., Anagnostopoulos, N.I., Christakis, J.I., Meletis, J., Bourantas, K.L., Zoumbos, N.C., Yataganas, X. & Viniou, N.A. (2002) Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. British Journal of Haematology, 118, 174189.
  • Tessitore, N., Solero, G.P., Lippi, G., Bassi, A., Faccini, G.B., Bedogna, V., Gammaro, L., Brocco, G., Restivo, G., Bernich, P., Lupo, A. & Maschio, G. (2001) The role of iron status markers in predicting response to intravenous iron in hemodialysis patients. Nephrology, Dialysis, Transplantation, 16, 14161423.
  • Thomas, C. & Thomas, L. (2002) Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clinical Chemistry, 48, 10661076.
  • Weiss, G. & Goodnough, L. (2005) Anemia of chronic disease. New England Journal of Medicine, 352, 10111023.
  • Weiss, G. & Gordeuk, V.R. (2005) Benefits and risks of iron therapy for chronic anaemias. European Journal of Clinical Investigation, 35, 3645.
  • Wright, J.R., Yng, Y.C., Julian, J.A., Pritchard, K.I., Whelan, T.J., Smith, C., Szechtman, B., Roa, W., Mulroy, L., Rudinskas, L., Gagnon, B., Okawara, G.S. & Levine, M.N. (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. Journal of Clinical Oncology, 25, 10271032.